WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314239
CAS#: 869113-09-7
Description: Umeclidinium bromide, also known as GSK-573719 or GSK-573719A, is an anticholinergic drug approved for use in combination with vilanterol (as umeclidinium bromide/vilanterol) for the treatment of chronic obstructive pulmonary disease (COPD).
MedKoo Cat#: 314239
Name: Umeclidinium bromide
CAS#: 869113-09-7
Chemical Formula: C29H34BrNO2
Exact Mass: 507.17729
Molecular Weight: 508.49
Elemental Analysis: C, 68.50; H, 6.74; Br, 15.71; N, 2.75; O, 6.29
Umeclidinium bromide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).
Related CAS #: 869185-19-3 (cation) 869113-09-7
Synonym: GSK-573719, GSK573719, GSK 573719, GSK-573719A, GSK573719A, GSK 573719A, Incruse Ellipta, Umeclidinium bromide
IUPAC/Chemical Name: Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
InChi Key: PEJHHXHHNGORMP-UHFFFAOYSA-M
InChi Code: InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
SMILES Code: OC(C1=CC=CC=C1)(C2=CC=CC=C2)C34CC[N+](CC4)(CCOCC5=CC=CC=C5)CC3.[Br-]
The following data is based on the product molecular weight 508.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD. Med Lett Drugs Ther. 2014 Apr 14;56(1440):30-1. Review. PubMed PMID: 24736248.
2: Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013 Oct 10;7:1201-8. doi: 10.2147/DDDT.S39449. eCollection 2013. Review. PubMed PMID: 24143077; PubMed Central PMCID: PMC3797618.
3: Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013 Dec;7(6):311-9. doi: 10.1177/1753465813499789. Epub 2013 Sep 3. Review. PubMed PMID: 24004659.